---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-230118"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:45:11.630138+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics cuts workforce 25%, extends cash runway into Q2 2026

## Summary
- Reducing workforce by approximately 25%, including reductions effective August 2025.
- Expected cash charges of $1.0-1.4 million, primarily severance, paid in Q4 2025.
- Cash runway extended into Q2 2026 based on current operating plans and cost savings.
- Company cites need to reduce costs to advance strategic priorities amid ongoing losses.

## SEC filing metadata
- accession: 0001193125-25-230118
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312525230118/0001193125-25-230118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312525230118/d63317d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-230118
- JSON: https://secwatch.observer/filing/0001193125-25-230118.json
- Plain text: https://secwatch.observer/filing/0001193125-25-230118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.